# Phase I/IIA Study of PET Imaging With 89Zr-Df-IAB2M in Metastatic Prostate Cancer

> **NCT01923727** · PHASE1,PHASE2 · COMPLETED · sponsor: **ImaginAb, Inc.** · enrollment: 38 (actual)

## Conditions studied

- Metastatic Prostate Cancer

## Interventions

- **BIOLOGICAL:** [89Zr]Df-IAB2M

## Key facts

- **NCT ID:** NCT01923727
- **Lead sponsor:** ImaginAb, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-08
- **Primary completion:** 2016-05
- **Final completion:** 2016-06
- **Target enrollment:** 38 (ACTUAL)
- **Last updated:** 2020-02-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01923727

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01923727, "Phase I/IIA Study of PET Imaging With 89Zr-Df-IAB2M in Metastatic Prostate Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01923727. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*